Cargando…

Second-line combination therapies in nonsmall cell lung cancer without known driver mutations

In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination chemotherapy is standard treatment in the first-line setting; however, the large majority of patients ultimately progress. For more than a decade, single-agent therapy with docetaxel, pemetrexed or erlotinib has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Bluthgen, Maria-Virginia, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487623/
https://www.ncbi.nlm.nih.gov/pubmed/26621972
http://dx.doi.org/10.1183/16000617.00002115